Ardea’s HIV Drug Shows Once-Daily Potential In Phase II
This article was originally published in The Pink Sheet Daily
Executive Summary
NNRTI targets treatment-naive patients who cannot take BMS’ Sustiva, CEO says.
You may also be interested in...
Savient Seeks FDA Priority Review For Puricase
Savient is seeking a six-month priority review from FDA for its gout drug pegloticase (formerly Puricase), setting it up for an action date in late April if granted. The BLA, submitted Oct. 31, could face tough safety scrutiny at FDA, however, on cardiovascular events
Savient Seeks FDA Priority Review For Puricase
Savient is seeking a six-month priority review from FDA for its gout drug pegloticase (formerly Puricase), setting it up for an action date in late April if granted. The BLA, submitted Oct. 31, could face tough safety scrutiny at FDA, however, on cardiovascular events
Savient Seeks FDA Priority Review For Puricase
BLA for the gout drug was filed Oct. 31, but the application still could face challenges at FDA due to cardiovascular risk.